Posted from: Thursday, May 05, 2016 - 12:47 PM - Present

Descovy Approved for HIV-1 Treatment

April 4, 2016 – The FDA approved Gilead’s Descovy® for HIV-1 infection treatment in patients 12 years of age and older. The recommended dosage is one tablet daily.  Descovy® contains emtricitabine and tenofovir alafenamide, two HIV nucleoside analog reverse transcriptase inhibitors (NRTIs). Descovey is similar to Viread and Genvoya, both manufactured by Gilead as well, however Descovy includes a lower dosage of tenofovir alafenamide. Tenofovir alafenamide is effective in smaller doses reducing the risk of causing kidney damage and bone marrow density issues.  Descovy is now available.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

 

Last Updated Sunday, June 25, 2017 - 10:56 AM.